Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MetMAb · 2 trials · 2 indications
Progression-free survival was defined as the time from randomization to the first occurrence of progression or relapse (as per Response Evaluation Criteria in Solid Tumors (RECIST 1.0) and assessed by the site radiologist or investigator) or death on study from any cause (within 30 days of last treatment).
Progression-free survival (PFS) in participants with Met Diagnostic-Positive tumors as determined by immunohistochemistry. PFS was defined as the time from randomization to the first occurrence of progression or relapse (as per Response Evaluation Criteria in Solid Tumors (RECIST 1.0) and assessed by the site radiologist or investigator) or death on study from any cause (within 30 days of last treatment).
| Arm | Type | Description |
|---|---|---|
| MetMAb + Erlotinib | EXPERIMENTAL | MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity. |
| Placebo + Erlotinib | PLACEBO_COMPARATOR | Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity. |
| Stage I | EXPERIMENTAL | - |
| Stage II | EXPERIMENTAL | - |
| Stage III | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Erlotinib HCl | DRUG | Erlotinib 150 mg oral dose once daily. |
| MetMAb | DRUG | MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks. |
| placebo (0.9 % saline) | DRUG | Placebo Intravenous infusion every 3 weeks. |
| bevacizumab | DRUG | Repeating intravenous dose |
Inclusion Criteria: Patients must meet the following criteria for study entry: * Histologically confirmed NSCLC * Availability of a tumor specimen * Recurrent or progressive disease following at least one chemo containing regimen for Stage IIIB/IV disease * Measurable disease in accordance with Re...
Top 20 of 84 competitors
MetMAb is an investigational drug studied for use in advanced Non-Small Cell Lung Cancer. It was evaluated in a Phase 2 clinical trial in combination with Tarceva (erlotinib) for patients with this condition. MetMAb is also being studied for solid cancers, but it is not approved and remains in clinical development.
MetMAb is a monovalent antagonist antibody that targets the receptor c-Met. By binding to c-Met, it is designed to block signaling through this receptor, which is involved in cancer cell growth and survival. This mechanism was evaluated in clinical trials for solid tumors and Non-Small Cell Lung Cancer.
MetMAb is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the pharmaceutical company responsible for advancing this investigational drug through clinical trials for oncology indications.
MetMAb is in Phase 2 clinical development. It has completed a Phase 2 trial in Non-Small Cell Lung Cancer and a Phase 1 trial in solid cancers. MetMAb is investigational and has not been approved by regulatory authorities.
MetMAb has been studied in two completed clinical trials. NCT00854308 was a Phase 2 study of MetMAb combined with Tarceva (erlotinib) in advanced Non-Small Cell Lung Cancer with 137 participants. NCT01068977 was a Phase 1 study of MetMAb alone in patients with locally advanced or metastatic solid tumors with 44 participants.
Yes, MetMAb is also known as PRO143966. In clinical trial records, it is referred to as MetMAb (PRO143966), a monovalent antagonist antibody to the receptor c-Met. Both names refer to the same investigational drug being developed by Roche.